2. The following offences may be compounded in accordance with section 65 of the Act by the Chief Executive or any officer of the Authority authorised in writing in that behalf by the Chief Executive:| (a) | an offence under section 12(6)(a), 13(6)(a), 14(4), 15(2), 16(2)(a), 17(3), 18(2), 19(2), 20(3), 21(3), 23(3)(a), 35(4), 36(5), 40(3), 41(2), 42(5)(a), 43(3), 44(3)(a), 49(5)(e), (9) or (11), 50 or 66(4) of the Act; | | (aa) | an offence under section 47(4) of the Act relating to a contravention of a regulation in the Health Products (Active Ingredients) Regulations 2023 (G.N. No. S 831/2023), except an offence relating to a contravention of regulation 4 or 5 of those Regulations; [S 832/2023 wef 18/12/2023] | | (b) | an offence under regulation 4(3), 10(3) or 11(4)(a) of the Health Products (Cosmetic Products – ASEAN Cosmetic Directive) Regulations 2007 (G.N. No. S 683/2007); | | (c) | an offence under regulation 13A(3), 31(5), 32(2), 36A(5), 37, 38(3), 39(3), 39A(3), 39B(3), 40(2), 41(3), 43(2), 44(4), 45(3), 46(4), 47(3), 48(6) or (7)(b) or 49(5) or (6)(b) of the Health Products (Medical Devices) Regulations 2010 (G.N. No. S 436/2010); [S 540/2016 wef 01/11/2016] | | (d) | an offence under regulation 21(4), 31(3), 32(4), 33(3), 40, 41(6) or (7)(b), 42(4) or (5)(b), 43(2), 44(3), 45(2), 46(8), 48(7) or 65(3) of the Health Products (Therapeutic Products) Regulations 2016 (G.N. No. S 329/2016); [S 540/2016 wef 01/11/2016] | | (e) | an offence under regulation 7(5) of the Health Products (Licensing of Retail Pharmacies) Regulations 2016 (G.N. No. S 330/2016); [S 540/2016 wef 01/11/2016] | | (f) | an offence under regulation 15(2) of the Health Products (Advertisement of Therapeutic Products) Regulations 2016 (G.N. No. S 333/2016), renamed as the Health Products (Advertisement of Specified Health Products) Regulations 2016 from 1 March 2021; [S 540/2016 wef 01/11/2016] [S 150/2021 wef 08/03/2021] | | (g) | an offence under regulation 29(1)(a) of the Health Products (Clinical Trials) Regulations 2016 (G.N. No. S 331/2016) but only in respect of a contravention of regulation 4(4) or (6), 5(1), (2), (3), (4) or (6), 6, 7(2), 8(1), 9(1), 10(1), (2), (4) or (6), 11(1), (2) or (3), 12(1), (2), (3) or (4), 13(1) or (2), 14, 15, 16(1) or (9), 17(3), (4) or (5), 18(1), 19(3), 22(2), 23(1) or (3), 23A(1), (3) or (4), 24(1), (2) or (4), 25(1), (2), (3) or (4) or 26(1), (2), (3) or (4) of those Regulations; [S 540/2016 wef 01/11/2016] [S 150/2021 wef 08/03/2021] | | (h) | an offence under regulation 24(1)(a) of the Health Products (Therapeutic Products as Clinical Research Materials) Regulations 2016 (G.N. No. S 332/2016), renamed as the Health Products (Clinical Research Materials) Regulations 2016 from 1 March 2021; [S 540/2016 wef 01/11/2016] [S 150/2021 wef 08/03/2021] | | (i) | an offence under regulation 17(3), 19(5), 23, 24(5) or (6)(a), 25(3), 26(3) or 27(2) of the Health Products (Oral Dental Gums) Regulations 2016 (G.N. No. S 539/2016); [S 540/2016 wef 01/11/2016] [S 150/2021 wef 08/03/2021] | | (j) | an offence under regulation 28(4), 32(3), 33(4), 34(5), 35(3), 44, 45(6) or (7)(b), 46(2), 48(4) or (5)(b), 49(2), 50(3), 51(2) or 56(3) of the Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (G.N. No. S 104/2021). [S 150/2021 wef 08/03/2021] |
|
